AN-788
| Clinical data | |
|---|---|
| Other names | AN788; NSD-788; NSD788; IP-2018; IP2018 |
| Drug class | Monoamine reuptake inhibitor; Serotonin–dopamine reuptake inhibitor |
| Identifiers | |
| CAS Number | |
AN-788, also known as NSD-788 and IP-2018, is an experimental drug which was originated by NeuroSearch and is under development by Saniona for the treatment of major depressive disorder.[1][2][3][4] It was also under development for anxiety disorders, but development for this indication was discontinued.[1] The drug acts as a serotonin–dopamine reuptake inhibitor (SDRI).[1][3][4] As of November of 2018, it is in an agreement for phase II clinical trials for major depressive disorder.[5] As of September 2022, no recent development has been reported for major depressive disorder, but the drug is now in phase 2 clinical trials for erectile dysfunction.[1]
See also
[edit]References
[edit]- 1 2 3 4 "Initiator Pharma". 8 November 2018.
- ↑ "Delving into the Latest Updates on IP-2018 with Synapse". Synapse. 1 November 2024. Retrieved 2 November 2024.
- 1 2 Shao L, Li W, Xie Q, Yin H (February 2014). "Triple reuptake inhibitors: a patent review (2006 - 2012)". Expert Opinion on Therapeutic Patents. 24 (2): 131–154. doi:10.1517/13543776.2014.859676. PMID 24289044. S2CID 1825304.
- 1 2 Bang-Anderssen B, Bøgesø KP, Kehler J, Sánchez C (16 December 2016). "New Trends in Antidepresent Drug Research". In Ecker GF, Clausen RP, Sitte HH (eds.). Transporters as Drug Targets. Wiley. pp. 36–. ISBN 978-3-527-67951-5.
- ↑ "Initiator Pharma signs option agreement for Phase 2 ready drug candidate". News Powered by Cision. 8 November 2018. Retrieved 2022-02-08.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information. |